

Publikationen 2024

1. Allanore Y, Khanna D, Smith V, Aringer M, Hoffmann-Vold AM, Kuwana M, Merkel PA, Stock C, Sambevski S, Denton CP; SENSICIS trial investigators. Effects of nintedanib in patients with limited cutaneous systemic sclerosis and interstitial lung disease. **Rheumatology (Oxford)** 2024; 63: 639-647.
2. Wohland H, Aringer M, Leuchten N. Physical exercise is associated with less fatigue, less pain and better sleep in patients with systemic lupus erythematosus. **Clin Exp Rheumatol** 2024; 42: 601-607.
3. Fanouriakis A, Kostopoulou M, Andersen J, Aringer M, Arnaud L, Bae SC, Boletis J, Bruce IN, Cervera R, Doria A, Dörner T, Furie RA, Gladman DD, Houssiau FA, Inês LS, Jayne D, Kouloumas M, Kovács L, Mok CC, Morand EF, Moroni G, Mosca M, Mucke J, Mukhtyar CB, Nagy G, Navarra S, Parodis I, Pego-Reigosa JM, Petri M, Pons-Estel BA, Schneider M, Smolen JS, Svenungsson E, Tanaka Y, Tektonidou MG, Teng YO, Tincani A, Vital EM, van Vollenhoven RF, Wincup C, Bertsias G, Boumpas DT. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. **Ann Rheum Dis** 2024; 83: 15-29.
4. Kumar C, Kuhn M, Herrmann K, Leuchten N, Aringer M. Severe methotrexate toxicity in elderly patients under diuretics. **RMD Open** 2024; 10: e003827.
5. Nielsen W, Strand V, Simon LS, Parodis I, Kim AHJ, Desai M, Enman Y, Wallace D, Chaichian Y, Navarra S, Aranow C, MacKay M, Trotter K, Tayer-Shifman OE, Duarte-Garcia A, Shan Tam L, Ugarte-Gil MF, PonsEstel GJ, Reynolds JA, Nikpour M, Hoi A, Romero-Diaz J, Papachristos D, Aggarwal A, Mok CC, Fujio K, Ramsey-Goldman R, Howe A, Kia BN, Bonilla D, Thumboo J, Mosca M, Aringer M, Johnson SR, Drucker AM, Morand E, Bruce I, Touma Z; OMERACT SLE Working Group. OMERACT 2023 Systemic Lupus Erythematosus Special Interest Group: Winnowing and Binning Preliminary Candidate Domains for the Core Outcome Set. **Semin Arthritis Rheum** 2024; 65: 152380.
6. Albrecht K, Thiele K, Alexander T, Aringer M, Eidner T, Henes J, Hoese G, Karberg K, Kiltz U, Krause A, Ochs W, Richter JG, Späthling-Mestekemper S, Steinmüller M, Wassenberg S, Strangfeld A, Callhoff J. Aktuelle Zahlen zur rheumatologischen Versorgung –Jahresbericht aus der Kerndokumentation der regionalen kooperativenRheumazentren. **Z Rheumatol** 2024; 83: 666-674.
7. Wallmeier P, Arnold S, Tais A, Ihorst G, Janoschke M, Schubach F, Aries P, Bergner R, Bremer JP, Görl N, Gutdeutsch E, Hellmich B, Henes J, Hoyer BF, Kangowski A, Kötter I, Krusche M, Magnus T, Metzler C, Müller-Ladner U, Schaier M, Schönermarck U, Thiel J, Unger L, Venhoff N, Weinmann-Menke J, Petersen J, Lamprecht P, Iking-Konert C. The Joint Vasculitis Registry in German-speaking countries (GeVas): subgroup analysis of 195 GCA patients. **Clin Exp Rheumatol** 2024; 42: 895-904.
8. Arnold S, Wallmeier P, Tais A, Ihorst G, Janoschke M, Schubach F, Aries P, Bergner R,

- Bremer JP, Görl N, Gutdeutsch E, Hellmich B, Henes J, Hoyer BF, Kangowski A, Kötter I, Krusche M, Magnus T, Metzler C, Müller-Ladner U, Petersen J, Reichelt de Tenorio A, Schaier M, Schirmer JH, Schönermarck U, Thiel J, Unger L, Venhoff N, Weinmann-Menke J, Iking-Konert C, Lamprecht P. The Joint Vasculitis Registry in German-speaking countries (GeVas): subgroup analysis of 266 AAV patients. **Clin Exp Rheumatol** 2024; 42: 852-858.
9. Lützner J, Deckert S, Lange T, Postler AE, Aringer M, Berth H, Bork H, Dreinhöfer KE, Günther KP, Heller KD, Hube R, Kirschner S, Kladny B, Kopkow C, Sabatowski R, Stoeve J, Wagner R, Lützner C. Evidenzbasierte und patientenorientierte Indikationsstellung zur Knieendoprothese–Update der Leitlinie. **Z Orthop Unfall** 2024; May 29 Epub. doi: 10.1055/a-2288-7254.
 10. Merrill JT, Tanaka Y, D'Cruz D, Vila-Rivera K, Siri D, Zeng X, Saxena A, Aringer M, D'Silva KM, Cheng L, Mohamed MF, Siovitz L, Bhatnagar S, Gaudreau MC, Doan TT, Friedman A. Efficacy and safety of upadacitinib or elsubrutinib alone or in combination for patients with systemic lupus erythematosus: A phase 2 randomized controlled trial. **Arthritis Rheumatol** 2024; 76: 1518-1529.
 11. Nielsen W, Strand V, Simon L, Pinsker E, Bonilla D, Morand E, Thumboo J, Aringer M, Mosca M, Bruce I, Parodis I, Kim A, Desai M, Enman Y, Shea B, Wallace DJ, Chaichian Y, Navarra S, Aranow C, Mackay M, Trotter K, Tayer-Shifman OE, Duarte-García A, Shan Tam L, Ugarte-Gil MF, Pons-Estel GJ, Reynolds JA, Nikpour M, Hoi A, Romero-Diaz J, Aggarwal A, Mok CC, Fujio K, Ramsey-Goldman R, Gladman DD, Arnaud L, Bultink IEM, Ruiz-Irastorza G, Inês LS, Appenzeller S, Dobrowolski C, Clarke AE, Kamen DL, Barracough M, Tani C, Gómez-Puerta JA, Werth VP, Katz P, Nowrouzi-Kia B, Johnson SR, Drucker AM, Touma Z; OMERACT SLE Working Group. OMERACT systemic lupus erythematosus domain survey. **Semin Arthritis Rheum** 2024 68: 152520.
 12. Major TJ, Takei R, Matsuo H, Leask MP, Sumpter NA, Topleless RK, Shirai Y, Wang W, Cadzow MJ, Phipps-Green AJ, Li Z, Ji A, Merriman ME, Morice E, Kelley EE, Wei WH, McCormick SPA, Bixley MJ, Reynolds RJ, Saag KG, Fadason T, Golovina E, O'Sullivan JM, Stamp LK, Dalbeth N, Abhishek A, Doherty M, Roddy E, Jacobsson LTH, Kapetanovic MC, Melander O, Andrés M, Pérez-Ruiz F, Torres RJ, Radstake T, Jansen TL, Janssen M, Joosten LAB, Liu R, Gaal OI, Crişan TO, Rednic S, Kurreeman F, Huizinga TWJ, Toes R, Lioté F, Richette P, Bardin T, Ea HK, Pascart T, McCarthy GM, Helbert L, Stibůrková B, Tausche AK, Uhlig T, Vitart V, Boutin TS, Hayward C, Riches PL, Ralston SH, Campbell A, MacDonald TM; FAST Study Group; Nakayama A, Takada T, Nakatochi M, Shimizu S, Kawamura Y, Toyoda Y, Nakaoka H, Yamamoto K, Matsuo K, Shinomiya N, Ichida K; Japan Gout Genomics Consortium; Lee C; Asia Pacific Gout Consortium; Bradbury LA, Brown MA, Robinson PC, Buchanan RRC, Hill CL, Lester S, Smith MD, Rischmueller M, Choi HK, Stahl EA, Miner JN, Solomon DH, Cui J, Giacomini KM, Brackman DJ, Jorgenson EM; GlobalGout Genetics Consortium; Liu H, Susztak K; 23andMe Research Team; Shringarpure S, So A, Okada Y, Li C, Shi Y, Merriman TR. A genome-wide association analysis reveals new pathogenic pathways in gout. **Nat Genet** 2024; 56: 2392-2406.
 13. Aringer M, Finzel S, Voll RE. Immunpathogenese des systemischen Lupus erythematoses. **Z Rheumatol** 2024; 83: 68-76.
 14. Aringer M, Mosca M. SLE criteria are by necessity still based on clinical (and immunological) criteria items. **Expert Rev Clin Immunol** 2024; 20: 305-311.
 15. Aringer M, Yazdany J. For SLE activity and glucocorticoids: aim low. **Lancet Rheumatol** 2024; 6: e496-e498.

16. Mucke J, Aringer M. Die 2023 EULAR-Empfehlungen zur Behandlung des systemischen Lupus erythematoses – Implikationen für die Versorgung in Deutschland. **Z Rheumatol** 2024; 83: 431-438.
17. Hellmich B, Mucke J, Aringer M. Head-to-Head-Studien bei Kollagenosen und Vaskulitiden. **Z Rheumatol** 2024; 83: 620-628.
18. Aringer M, Distler O, Hoffmann-Vold AM, Kuwana M, Prosch H, Volkmann ER. Rationale for phosphodiesterase-4 inhibition as a treatment strategy for interstitial lung diseases associated with rheumatic diseases. **RMD Open** 2024; 10: e004704.
19. Sockel K, Götze K, Ganster C, Bill M, Georgi JA, Balaian E, Aringer M, Trautmann-Grill K, Uhlig M, Bornhäuser M, Haase D, Thiede C. VEXAS syndrome: complete molecular remission after hypomethylating therapy. **Ann Hematol** 2024; 103: 993-997.